{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:46Z","timestamp":1774343086143,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171078"],"award-info":[{"award-number":["82171078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>COVID-19 vaccination is considered the most effective and promising approach for the elimination of the SARS-CoV-2 pandemic globally. Although the vaccine has been proven to be safe, as evidenced by the promotion of mass vaccination, new side effects, including several ocular complications that were not described during the experimental stage, are now emerging. In the present study, we report a 33-year-old Chinese man who developed probable Vogt\u2013Koyanagi\u2013Harada (VKH) disease only one day after his first dose of an inactivated COVID-19 vaccine, without any systemic symptoms. His medical history was unremarkable, except for hypertension. Although successfully relieved by oral prednisone, the patient progressed to the chronic stage of VKH disease with ocular depigmentation 4 months after onset. By reviewing similar cases previously reported, we discuss and summarize the common characteristics of VKH disease associated with vaccines against SARS-CoV-2, as well as the possible mechanisms behind this phenomenon. Although the causality is unclear, ophthalmologists and generalists should be aware of this possible ocular adverse effect after COVID-19 vaccination.<\/jats:p>","DOI":"10.3390\/vaccines10050783","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T21:36:06Z","timestamp":1652736966000},"page":"783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Probable Vogt\u2013Koyanagi\u2013Harada Disease after COVID-19 Vaccination: Case Report and Literature Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-8178","authenticated-orcid":false,"given":"Xinyi","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031, China"},{"name":"Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia of National Health Commission, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai 200031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031, China"},{"name":"Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia of National Health Commission, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai 200031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Angioni, R., Sasset, L., Cioccarelli, C., S\u00e1nchez-Rodr\u00edguez, R., Bertoldi, N., Putaggio, C.C., Viola, A., Cattelan, A., and Molon, B. (2022). COVID-19 Vaccination Limits Systemic Danger Signals in SARS-CoV-2 Infected Patients. Viruses, 14.","DOI":"10.3390\/v14030565"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Xu, W., Tang, J., Chen, C., Wang, C., Wen, W., Cheng, Y., Zhou, M., Wu, Q., Zhang, X., and Feng, Z. (2022). Safety and efficacy of the COVID-19 vaccine in children and\/or adolescents:A meta-analysis. J. Infect.","DOI":"10.1016\/j.jinf.2022.01.032"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/09273948.2021.1976221","article-title":"Ocular Adverse Events After COVID-19 Vaccination","volume":"29","author":"Ng","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Haseeb, A.A., Solyman, O., Abushanab, M.M., Abo Obaia, A.S., and Elhusseiny, A.M. (2022). Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines, 10.","DOI":"10.3390\/vaccines10020342"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e9914","DOI":"10.1097\/MD.0000000000009914","article-title":"Association of human leukocyte antigen (HLA)-DQ and HLA-DQA1\/DQB1 alleles with Vogt-Koyanagi-Harada disease: A systematic review and meta-analysis","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00006982-199616020-00013","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in the vitreous from a patient with Vogt-Koyanagi-Harada syndrome","volume":"16","author":"Bassili","year":"1996","journal-title":"Retina"},{"key":"ref_12","first-page":"289","article-title":"High inducibility of Epstein-Barr virus replication in B lymphocytes in Vogt-Koyanagi-Harada disease","volume":"103","author":"Minoda","year":"1999","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10792-006-9020-y","article-title":"Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease","volume":"27","author":"Sugita","year":"2007","journal-title":"Int. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.ajoc.2020.100793","article-title":"Vogt-Koyanagi-Harada disease presenting secondary to a post-infectious Mycoplasma pneumoniae autoimmune response","volume":"19","author":"Wade","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2169\/internalmedicine.9819-17","article-title":"Vogt-Koyanagi-Harada Disease Associated with Influenza A Virus Infection","volume":"57","author":"Yoshino","year":"2018","journal-title":"Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s40064-016-2223-4","article-title":"Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis","volume":"5","author":"Dogan","year":"2016","journal-title":"Springerplus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4103\/ijo.IJO_2550_21","article-title":"Vogt Koyanagi Harada disease following a recent COVID-19 infection","volume":"70","author":"Anthony","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_18","first-page":"1","article-title":"SARS-CoV-2 among the Potential Viral Triggers for Vogt-Konayagi-Harada Disease: First Case Report and Literature Review","volume":"2021","author":"Santamaria","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40942-021-00319-3","article-title":"Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine","volume":"7","author":"Saraceno","year":"2021","journal-title":"Int. J. Retina Vitr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/OPX.0000000000001523","article-title":"Case Report: Posterior Uveitis after Divalent Human Papillomavirus Vaccination in an Asian Female","volume":"97","author":"Ye","year":"2020","journal-title":"Optom. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/09273948.2019.1661498","article-title":"Vogt-Koyanagi-Harada-like Disease following Yellow Fever Vaccination","volume":"29","author":"Campos","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/09273948.2018.1483520","article-title":"Vogt-Koyanagi-Harada Disease Associated with Hepatitis B Vaccination","volume":"27","author":"Sood","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_23","unstructured":"World Health Organization (2019). Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification, World Health Organization. [2nd ed.]. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241516990."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijid.2021.09.075","article-title":"Bilateral uveitis after inoculation with COVID-19 vaccine: A case report","volume":"113","author":"Pan","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1756-185X.14259","article-title":"COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells","volume":"25","author":"Mahroum","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., and Naffaa, M.E. (2021). Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9050435"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: Modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108721","DOI":"10.1016\/j.clim.2021.108721","article-title":"COVID-19 vaccine and autoimmunity: Awakening the sleeping dragon","volume":"226","author":"Akinosoglou","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.34067\/KID.0005372021","article-title":"Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases","volume":"2","author":"Caza","year":"2021","journal-title":"Kidney360"},{"key":"ref_31","first-page":"1","article-title":"Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine","volume":"2022","author":"Kim","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101404","DOI":"10.1016\/j.ajoc.2022.101404","article-title":"Acute-onset Vogt-Koyanagi-Harada like uveitis following COVID-19 inactivated virus vaccination","volume":"26","author":"Chen","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/ijo.IJO_2589_21","article-title":"Harada-like syndrome post-Covishield vaccination: A rare adverse effect","volume":"70","author":"Reddy","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"De Domingo, B., Lopez, M., Lopez-Valladares, M., Ortegon-Aguilar, E., Sopena-Perez-Arguelles, B., and Gonzalez, F. (2022). Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine. Cells, 11.","DOI":"10.3390\/cells11061012"},{"key":"ref_35","first-page":"1","article-title":"Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination","volume":"2022","author":"Accorinti","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_36","first-page":"1","article-title":"De Novo Vogt-Koyanagi-Harada Disease following COVID-19 Vaccine: A Case Report and Literature Overview","volume":"2022","author":"Tisseyre","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/09273948.2021.1974492","article-title":"Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine","volume":"29","author":"Koong","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-021-00251-5","article-title":"Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination","volume":"11","author":"Papasavvas","year":"2021","journal-title":"J. Ophthalm. Inflamm. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/09273948.2021.1949478","article-title":"Panuveitis following Vaccination for COVID-19","volume":"29","author":"Mudie","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, X., Li, H., Li, M., and Gong, S. (2022). Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen. Vaccines, 10.","DOI":"10.3390\/vaccines10030482"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:07Z","timestamp":1760137867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["vaccines10050783"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10050783","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}